The COVID-19 Global Rheumatology Alliance: collecting data in a pandemic

The global COVID-19 pandemic has the potential to severely affect those with rheumatic diseases or who are taking immunosuppressive therapies. Information is lacking as to how these groups will fare if they become infected. A global alliance has rapidly formed to try to address this information deficit.

[1]  D. Furst.  The risk of infections with biologic therapies for rheumatoid arthritis. , 2010, Seminars in arthritis and rheumatism.

[2]  Zunyou Wu,et al.  Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. , 2020, JAMA.

[3]  A. Fontanet,et al.  Clinical features and viral diagnosis of two cases of infection with Middle East Respiratory Syndrome coronavirus: a report of nosocomial transmission , 2013, The Lancet.

[4]  Elizabeth Rea,et al.  Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area. , 2003, JAMA.

[5]  Lisa Rosenbaum,et al.  Facing Covid-19 in Italy - Ethics, Logistics, and Therapeutics on the Epidemic's Front Line. , 2020, The New England journal of medicine.

[6]  B. Cowling,et al.  A Comparative Study of Clinical Presentation and Risk Factors for Adverse Outcome in Patients Hospitalised with Acute Respiratory Disease Due to MERS Coronavirus or Other Causes , 2016, PloS one.

[7]  Peter Cameron,et al.  A major outbreak of severe acute respiratory syndrome in Hong Kong. , 2003, The New England journal of medicine.

[8]  Sharukh Lokhandwala,et al.  Characteristics and Outcomes of 21 Critically Ill Patients With COVID-19 in Washington State. , 2020, JAMA.

[9]  Yoshiya Tanaka,et al.  Herpes Zoster and Tofacitinib: Clinical Outcomes and the Risk of Concomitant Therapy , 2017, Arthritis & rheumatology.